SCHEDULE 13G: Perceptive Advisors Discloses 5.1% Stake in Beta Bionics, Inc.
Beneficial Ownership Report
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a beneficial ownership of 5.1% in Beta Bionics, Inc.'s common stock.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership in Beta Bionics, Inc.
- The Reporting Persons collectively beneficially own 2,203,840 shares of Beta Bionics, Inc. Common Stock.
- This ownership represents 5.1% of the total outstanding Common Stock of Beta Bionics, Inc.
- The ownership percentage is based on 43,356,281 shares of Common Stock outstanding as of April 30, 2025, as reported in Beta Bionics' Form 10-Q filed on May 6, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 2,203,840 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, leading to their deemed beneficial ownership.
- The acquisition of these securities was not for the purpose of changing or influencing the control of Beta Bionics, Inc.
Sentiment
Score: 6
Explanation: The disclosure of a significant institutional stake by a reputable life sciences investor is generally viewed positively, indicating confidence in the company, although the filing itself is purely informational and does not contain performance data.
Positives
- A significant institutional investor, Perceptive Advisors, has taken a 5.1% stake in Beta Bionics, Inc., potentially signaling confidence in the company's prospects.
- The investment is held by Perceptive Life Sciences Master Fund, Ltd., indicating a specialized focus on the life sciences sector, which aligns with Beta Bionics' business.
Future Outlook
NA
Management Comments
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.
Industry Context
This filing indicates a significant investment by a specialized life sciences fund in Beta Bionics, Inc., suggesting that the investor sees value or potential in the company within the broader healthcare and biotechnology sectors. Such investments can often be a positive signal for the industry segment the company operates in.
Stakeholder Impact
- Shareholders: The disclosure of a new significant institutional investor may positively influence investor sentiment and potentially the stock price, as it signals external validation of the company's value proposition.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement. |
| 04/30/2025 | Date as of which 43,356,281 shares of Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 05/06/2025 | Date Beta Bionics, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 05/15/2025 | Date of filing and signature for the Schedule 13G. |
Keywords
Beta Bionics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.